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extraction or pooled and subjected to sequential salt extraction to
purify the type II collagen. IsoAsp content was determined using
the PIMT assay (Promega).
Results: We identiﬁed PIMT activity in all of the EDTA extracts
we investigated suggesting the presence of widespread IsoAsp
(see Figure 2). We found no signiﬁcant difference (P=0.92) in
isoAsp content of cartilage comparing sites remote (28.4µM/g
cartilage, SEM 5.6) from the lesion to lesion sites (26.5µM/g
cartilage, SEM 4.8); we did ﬁnd a signiﬁcant difference (P=0.03)
between deep (99.9µM/g cartilage, SEM 31.7) and superﬁcial
cartilage (51.6µM/g cartilage, SEM 25.6) samples. We were also
able to measure isoAsp in paired synovial ﬂuid samples (mean
1.8µM/ml synovial ﬂuid, SEM 0.6). There were also detectable
levels of IsoAsp in our isolated and pooled type II collagen
fraction (mean 62.8pM/µg collagen).
As we identiﬁed signiﬁcant IsoAsp in cartilage we have inves-
tigated various ways of detecting IsoAsp hot spots. We have
modiﬁed the PIMT assay so that methyl groups are retained at
the IsoAsp location, Figure 3. We hope to use this approach in
conjunction with mass spectrometry to identify the corresponding
mass shifts in modiﬁed epitopes.
Conclusions: We have identiﬁed appreciable post-translational
damage in the form of IsoAsp in EDTA extracts of cartilage. We
were unable to identify differences in mean IsoAsp levels be-
tween cartilage lesions and sites remote from lesion suggesting
that apparently healthy appearing cartilage in an OA joint turns
over at rates similar to lesioned cartilage. We did however ﬁnd
a signiﬁcant difference between deep and superﬁcial cartilage
implying that the proteins deep within the cartilage had accu-
mulated more changes and so were older. We identiﬁed IsoAsp
in puriﬁed collagen suggesting that even this highly resistant
protein is susceptible to IsoAsp formation, which could lead to
instabilities in its structure with age. We have modiﬁed the PIMT
assay to retain a methyl group at IsoAsp sites and we hope to
develop this further to identify speciﬁc sites of isomerization.
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Purpose: To compare the levels of serum cartilage oligomeric
matrix protein (COMP) and aggrecan fetal epitope CS846,
two biochemical markers of cartilage degradation and abnor-
mal synthesis, respectively, between healthy volunteers, knee
osteoarthritis (OA) and anterior cruciate ligament (ACL) injury
patients.
Methods: Serum samples were collected at a single time point
from 36 patients divided into 3 groups: knee OA (N=12) mean
age (SD) 62.3 (8.5) yrs., ACL rupture (N=12) mean age 48.2
(16.3) yrs. and healthy (N=12) mean age 49.2(10.2) yrs. COMP
and CS846 levels were analyzed were measured using Elisa
assays (AnaMar Medical & IBEX Technologies Inc.).
Results: There was a statistically signiﬁcant difference in both
serum CS846 (p=0.01) and COMP (p =0.039) values between
the three groups as displayed in Figures 1 & 2.
CS846 levels were signiﬁcantly higher in OA patients vs. healthy
Figure 1. CS846 value in ACL, Normal and OA groups.
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Figure 2. COMP value in ACL, Normal and OA groups.
and ACL patients (p<0.01). There was no signiﬁcant difference in
CS846 levels between ACL patients and those who were healthy
(p=0.18). Likewise, COMP levels were signiﬁcantly higher in OA
patients vs. healthy and ACL patients (p<0.04). Again, there was
no signiﬁcant difference in COMP levels between ACL patients
and those who were healthy (p=0.95).
Conclusions: In this study, CS846 and COMP markers were
signiﬁcantly higher in knee OA patients than ACL patients and
healthy volunteers suggesting that OA patients are undergoing
more cartilage degeneration and attempt at cartilage repair than
the other groups. The lack of signiﬁcant differences between the
ACL and healthy groups may reﬂect the young age of the ACL
patients, the relatively short time since injury (average 3.4 yrs) or
perhaps the time dependent nature of attempted cartilage repair.
In addition, because these values are systemic and not localized
to the knee, lower average values may reﬂect overall generally
healthy cartilage which may mask higher levels at the site of
injury.
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Purpose: Disease-modifying anti-rheumatic drugs (DMARDs)
suppress inﬂammation, and retard cartilage degradation and
bone erosion in arthritis. The molecular mechanisms of action
of many traditional DMARDs are not known in detail. Their
effects on macrophages and synovial cells have been inves-
tigated but very little is known on their effects on cartilage
and inﬂammatory factors produced by affected chondrocytes.
Inducible prostaglandin synthase (cyclooxygenase-2, COX-2) is
expressed in rheumatoid and osteoarthritic cartilage and pro-
duces high amounts of proinﬂammatory prostanoids in the joint.
Mitogen-activated protein kinases (MAPKs) are a family of ser-
ine/threonine kinases that mediate inﬂammatory and other extra-
cellular signals to intracellular target proteins, e.g. transcription
factors that regulate gene expression. In the present study, we
investigated the effects of different DMARDs on interleukin-1β
(IL-1β) -induced COX-2 expression and further, aurothiomalate’s
effects and mechanisms of action in chondrocyte cultures and in
human cartilage in more detail.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA. Im-
mortalized H4 murine chondrocytes* were used in cell culture
experiments.
Results: In the present study, we investigated the effects of tra-
ditional DMARDs on COX-2 expression in chondrocytes. Unlike
the other tested compounds (cyclosporin A, hydroxychloroquine,
leﬂunomide, its active metabolite A771726, methotrexate and
sulfasalazine), aurothiomalate was found to be effective at clini-
cally relevant drug concentrations. Aurothiomalate inhibited IL-1β
-induced prostaglandin E2(PGE2) production in chondrocytes
and in human cartilage. Aurothiomalate inhibited also COX-2
expression by destabilizing its mRNA as did p38 MAPK inhibitor
SB203580. Interestingly, aurothiomalate inhibited the phospho-
rylation of JNK and p38 MAPKs, which may well explain its
inhibitory effect on COX-2 expression and PGE2 production in
chondrocytes.
Conclusions: The results provide a novel mechanism for the
anti-inﬂammatory action of aurothiomalate through reduced p38
and JNK MAPK activation and COX-2 expression, and stress
chondrocytes and their products as important targets in drug
development for arthritis.
*Murine H4 chondrocyte cell line was kindly provided by Peter
van der Kraan from Laboratory of Experimental Rheumatology,
University Medical Center Nijmegen, The Netherlands.
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Purpose and aim: Nitric oxide (NO) is an important mediator
of inﬂammation and joint destruction in rheumatoid arthritis (RA)
and osteoarthritis (OA). Oxygen reactive species induced by
NO can transform tyrosine residues of joint tissue proteins into
nitrosylated modiﬁed forms. An ELISA recognizing speciﬁcally
degradation fragments of the nitrosylated-modiﬁed telopeptide
(IIINys) of type III collagen -an abundant protein of synovial
tissue- has been developed and increased circulating IIINys
levels were found in patients with active RA. However, the tissue
origin of IIINys was not determined and no data in OA has yet
been reported. The aim of this study was to investigate whether
type III collagen nitrosylation can be detected in the synovial
tissue of patients with OA and RA and be reﬂected by changes
in synovial ﬂuid and circulating IIINys levels.
Methods: Synovial tissue of the knee joint was obtained from
patients with knee OA (n= 4), patients with RA (n=5) and non-
arthritic controls (n = 2) during joint replacement. Levels of IIINys
were measured by ELISA in knee joint ﬂuid and paired plasma
samples from 11 patients with knee OA and 11 patients with
active RA. We also measured circulating IIINys levels in 89
patients with painful knee OA (79% women; mean age 63.0;
mean disease duration 6.1 years, radiological Kellgren-Lawrence
score II or III), 55 patients with active RA (65% female, mean
age: 55 years, mean disease duration 14 years) and 83 healthy
women and men (20 to 60 yrs of age)
